Noxopharm Limited
NOXOF · OTC
6/30/2024 | 12/30/2023 | 6/30/2023 | 12/30/2022 | |
|---|---|---|---|---|
| Revenue | $1,794 | $606 | $1,332 | $1,673 |
| % Growth | 196.1% | -54.5% | -20.4% | – |
| Cost of Goods Sold | $2,934 | $1 | $2,426 | $2,897 |
| Gross Profit | -$1,140 | $605 | -$1,094 | -$1,225 |
| % Margin | -63.5% | 99.9% | -82.1% | -73.2% |
| R&D Expenses | $1,484 | $1,451 | $2,426 | $2,897 |
| G&A Expenses | $780 | $261 | $289 | $450 |
| SG&A Expenses | $2,046 | $2,019 | $1,413 | $1,513 |
| Sales & Mktg Exp. | -$1,700 | $1,758 | $96 | $1,063 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,530 | $3,470 | $3,714 | $1,517 |
| Operating Income | -$4,064 | -$3,471 | -$2,513 | -$2,810 |
| % Margin | -226.5% | -572.7% | -188.6% | -168% |
| Other Income/Exp. Net | $4,196 | -$239 | $118 | $96 |
| Pre-Tax Income | $132 | -$3,710 | -$4,815 | -$2,713 |
| Tax Expense | $1,212 | -$1,212 | $0 | $0 |
| Net Income | -$1,080 | -$2,498 | -$4,815 | -$2,713 |
| % Margin | -60.2% | -412.2% | -361.4% | -162.2% |
| EPS | -0.004 | -0.009 | -0.017 | -0.009 |
| % Growth | 56.5% | 48.5% | -77.4% | – |
| EPS Diluted | -0.004 | -0.009 | -0.017 | -0.009 |
| Weighted Avg Shares Out | 292,258 | 292,238 | 292,251 | 291,758 |
| Weighted Avg Shares Out Dil | 292,238 | 292,238 | 292,238 | 292,238 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $7 | $7 | $28 |
| Interest Expense | $5 | $26 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $6 | $72 |
| EBITDA | -$3,471 | -$1,129 | -$2,507 | -$2,738 |
| % Margin | -193.4% | -186.3% | -188.2% | -163.7% |